Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
5.00
+0.04 (0.81%)
Jun 5, 2025, 10:15 AM - Market open
Aptevo Therapeutics Employees
Aptevo Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 3 or -7.50% compared to the previous year.
Employees
37
Change (1Y)
-3
Growth (1Y)
-7.50%
Revenue / Employee
n/a
Profits / Employee
-$640,649
Market Cap
3.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
APVO News
- 14 days ago - Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - Accesswire
- 21 days ago - Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - Accesswire
- 4 weeks ago - Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - Accesswire
- 6 weeks ago - Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 6 weeks ago - Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Accesswire
- 2 months ago - RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment - Accesswire